Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease

Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease

Summary: The pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19). Worldwide efforts are being made to develop vaccines to mitigate this pandemic. We engineered two recombinant Newcastle disease virus (NDV) vectors expressing eithe...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Bryce M. Warner, Lisa A. Santry, Alexander Leacy, Mable Chan, Phuc H. Pham, Robert Vendramelli, Yanlong Pei, Nikesh Tailor, Emelissa Valcourt, Anders Leung, Shihua He, Bryan D. Griffin, Jonathan Audet, Marnie Willman, Kevin Tierney, Alixandra Albietz, Kathy L. Frost, Jacob G.E. Yates, Robert C. Mould, Lily Chan, Yeganeh Mehrani, Jason P. Knapp, Jessica A. Minott, Logan Banadyga, David Safronetz, Heidi Wood, Stephanie Booth, Pierre P. Major, Byram W. Bridle, Leonardo Susta, Darwyn Kobasa, Sarah K. Wootton
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Immune respons
Virology
Science
Q
Acceso en línea:https://doaj.org/article/a9d6cd355eb7470ba0489696155667f5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Summary: The pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19). Worldwide efforts are being made to develop vaccines to mitigate this pandemic. We engineered two recombinant Newcastle disease virus (NDV) vectors expressing either the full-length SARS-CoV-2 spike protein (NDV-FLS) or a version with a 19 amino acid deletion at the carboxy terminus (NDV-Δ19S). Hamsters receiving two doses (prime-boost) of NDV-FLS developed a robust SARS-CoV-2-neutralizing antibody response, with elimination of infectious virus in the lungs and minimal lung pathology at five days post-challenge. Single-dose vaccination with NDV-FLS significantly reduced SARS-CoV-2 replication in the lungs but only mildly decreased lung inflammation. NDV-Δ19S-treated hamsters had a moderate decrease in SARS-CoV-2 titers in lungs and presented with severe microscopic lesions, suggesting that truncation of the spike protein was a less effective strategy. In summary, NDV-vectored vaccines represent a viable option for protection against COVID-19.

Ejemplares similares